Quick Answer
Dogwood Therapeutics, Inc. reported Earnings Per Share Diluted of $7.13 (loss) per share for the year ending 2025.
- Dogwood Therapeutics, Inc. showed an increase of +43.1% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Dogwood Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $0.37 (loss) per share | Q2 2021: $0.51 (loss) per share | Q3 2021: $0.49 (loss) per share | Q1 2022: $0.48 (loss) per share | Q2 2022: $0.44 (loss) per share | Q3 2022: $0.28 (loss) per share | Q1 2023: $0.08 (loss) per share | Q2 2023: $0.08 (loss) per share | Q3 2023: $1.62 (loss) per share | Q1 2024: $1.68 (loss) per share | Q2 2024: $1.15 (loss) per share | Q3 2024: $2.05 (loss) per share | Q1 2025: $8.45 (loss) per share | Q2 2025: $1.99 (loss) per share | Q3 2025: $8.20 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Dogwood Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 239.5%.
- Historical annual values: Fiscal year 2025: $7.13 (loss) per share | Fiscal year 2024: $12.52 (loss) per share | Fiscal year 2023: $7.05 (loss) per share | Fiscal year 2022: $1.11 (loss) per share | Fiscal year 2021: $1.92 (loss) per share | Fiscal year 2020: $2.10 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: